The expression levels of some proliferation‐associated genes are associated with response to immune checkpoint inhibitors in NSCLC.19 Additionally, JAK1/2 mutations are associated with resistance to anti‐PD‐1/PD‐L1 antibodies20 and MDM2/MDM4 and EGFR alterations may correlate with hyperprogression.21, 22 The National Comprehensive Cancer Network guideline for NSCLC recommends PD‐1 inhibitors as first‐line treatment for patients with PD‐L1 expression ≥ 50% without EGFR or ALK mutations, and pembrolizumab for patients with PD‐L1 expression ≥ 1% as second‐line treatment. This evidence concerns the gene JAK1 and non-small cell lung carcinoma.